Publication | Open Access

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

Alzheimer's DiseaseOpen-label Extension StudyMedicineHereditary Transthyretin-mediated AmyloidosisNeurologyLong-term SafetyNeuropathologyPharmacology